TaleNeprilysin and Neprilysin inhibition in chronic kidney disease

TaleNeprilysin and Neprilysin inhibition in chronic kidney disease

<p><strong>Purpose of review </strong></p> Chronic kidney disease (CKD) is associated with increased risk of progression to end-stage kidney disease and cardiovascular events. There is limited evidence that available treatments have beneficial effects on cardiorenal outcomes...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Judge, PK, Haynes, R
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	Lippincott, Williams & Wilkins 2021

Gelijkaardige items

Neprilysin inhibition in chronic kidney disease.
door: Judge, P, et al.
Gepubliceerd in: (2014)

Chronic kidney disease, heart failure and neprilysin inhibition
door: Haynes, R, et al.
Gepubliceerd in: (2019)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
door: Kawa Dizaye, et al.
Gepubliceerd in: (2019-05-01)

Neprilysin Inhibitors and Bradykinin
door: Duncan J. Campbell, et al.
Gepubliceerd in: (2018-09-01)

2003 Mixed meal effects of neprilysin inhibition
door: Jessica R. Wilson, et al.
Gepubliceerd in: (2018-06-01)

Angiotensin Receptor-Neprilysin Inhibitor for Chronic Kidney Disease: Strategies for Renal Protection
door: Erika Hishida, et al.
Gepubliceerd in: (2024-10-01)

Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
door: In-Jeong Cho, et al.
Gepubliceerd in: (2021-12-01)

Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen.
door: Matthew Burrell, et al.
Gepubliceerd in: (2016-01-01)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
door: Nathalie Esser, et al.
Gepubliceerd in: (2022-06-01)

Application of Angiotensin Receptor–Neprilysin Inhibitor in Chronic Kidney Disease Patients: Chinese Expert Consensus
door: Liangying Gan, et al.
Gepubliceerd in: (2022-07-01)

Neprilysin as a Biomarker: Challenges and Opportunities
door: Noemi Pavo, et al.
Gepubliceerd in: (2020-08-01)

Relevance of Neutrophil Neprilysin in Heart Failure
door: Suriya Prausmüller, et al.
Gepubliceerd in: (2021-10-01)

Urinary neprilysin in the critically ill patient
door: Sahra Pajenda, et al.
Gepubliceerd in: (2017-05-01)

The role of neprilysin in regulating the hair cycle.
door: Naoko Morisaki, et al.
Gepubliceerd in: (2013-01-01)

Serum neprilysin levels are elevated in preeclampsia
door: Nevin Tüten, et al.
Gepubliceerd in: (2021-09-01)

Roles of Natriuretic Peptides and the Significance of Neprilysin in Cardiovascular Diseases
door: Hitoshi Nakagawa, et al.
Gepubliceerd in: (2022-07-01)

Urinary neprilysin – Another marker to predict postoperative acute kidney injury
door: Abhijit Nair, et al.
Gepubliceerd in: (2023-01-01)

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
door: A.S. Ryazanov, et al.
Gepubliceerd in: (2023-04-01)

Soluble neprilysin and survival in critically ill patients
door: Max Lenz, et al.
Gepubliceerd in: (2022-04-01)

Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure
door: Frederik H. Verbrugge, et al.
Gepubliceerd in: (2020-07-01)

Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension?
door: Sverre E. Kjeldsen, et al.
Gepubliceerd in: (2019-03-01)

Angiotensin Receptor‐Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension
door: Danial Sharifi Kia, et al.
Gepubliceerd in: (2020-07-01)

Breakthrough in Heart Failure therapy: LCZ696 combining ACE-Neprilysin inhibition
door: Sandeep Lahiry
Gepubliceerd in: (2017-01-01)

Adipolin, Chemerin, Neprilysin and Metabolic Disorders Associated with Obesity
door: Marcelina Sperling, et al.
Gepubliceerd in: (2023-07-01)

Active site mutations change the cleavage specificity of neprilysin.
door: Travis Sexton, et al.
Gepubliceerd in: (2012-01-01)

Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure
door: Julio Núñez, et al.
Gepubliceerd in: (2017-08-01)

Inhibition of neprilysin with sacubitril without RAS blockage aggravates renal disease in Dahl SS rats
door: Iuliia Polina, et al.
Gepubliceerd in: (2021-01-01)

Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF
door: Suriya Prausmüller, et al.
Gepubliceerd in: (2020-06-01)

The Association between Neprilysin gene polymorphisms and Alzheimer’s disease in Tibetan population
door: Siwei Chen, et al.
Gepubliceerd in: (2021-03-01)

Brain Shuttle Neprilysin reduces central Amyloid-β levels.
door: Christopher R Campos, et al.
Gepubliceerd in: (2020-01-01)

Elevated neprilysin in placental vesicles derived from preeclamptic pregnancies
door: Gill, M, et al.
Gepubliceerd in: (2018)

The effect of neprilysin and renin inhibition on the renal dysfunction following ischemia‐reperfusion injury in the rat
door: Fayez T. Hammad, et al.
Gepubliceerd in: (2021-03-01)

Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease
door: Yogesh N. V. Reddy, et al.
Gepubliceerd in: (2019-08-01)

Angiotensin-Neprilysin Inhibitor Therapy: A Retrospective Chart Study
door: Roda Plakogiannis, et al.
Gepubliceerd in: (2025-02-01)

Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion
door: Kangbo Li, et al.
Gepubliceerd in: (2023-02-01)

Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy.
door: Miners, J, et al.
Gepubliceerd in: (2006)

Amyloid beta and Alzheimer’s Disease: The role of neprilysin-2 in amyloid-beta clearance
door: Robert eMarr, et al.
Gepubliceerd in: (2014-08-01)

Engineering neprilysin activity and specificity to create a novel therapeutic for Alzheimer's disease.
door: Carl I Webster, et al.
Gepubliceerd in: (2014-01-01)

Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
door: Rolf Wachter, et al.
Gepubliceerd in: (2020-06-01)

Updates for Cardio‐Kidney Protective Effects by Angiotensin Receptor‐Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection
door: Shunichiro Tsukamoto, et al.
Gepubliceerd in: (2023-04-01)